CVM - AMEX

CEL-SCI Corporation

CEL-SCI Corporation

CVMยทAMEX

$7.17

-6.5%
HealthcareBiotechnology

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$49.27M
EPS-13.5000
P/E Ratio-2.82
Earnings Date01/12/2026
CEL-SCI Corporation

CEL-SCI Corporation Fair Value Envelope

CVM ยท AMEX

Our analysis suggests that CVM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.17, this represents a potential HIDDEN relative to our calculated worth for CEL-SCI Corporation.

HIDDEN
Intrinsic Value
Current Price: $7.17

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$326.3M
+ Cash & Equivalents$4.7M
Firm Value-$321.6M
- Debt$11.6M
Equity Value-$333.2M
/ Shares Outstanding6,871,587B
DCF Value-$48
OVERVALUED BY 776%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$22.3M
-$26.5M
-$31.4M
-$37.2M
-$44.1M
-$52.3M
-$62.0M
-$73.5M
-$87.2M
-$103.4M
Maintenance CapEx
-$22.5K
-$26.7K
-$31.6K
-$37.5K
-$44.5K
-$52.8K
-$62.6K
-$74.2K
-$88.0K
-$104.3K
Owner Earnings
-$22.3M
-$26.5M
-$31.4M
-$37.2M
-$44.2M
-$52.4M
-$62.1M
-$73.6M
-$87.3M
-$103.5M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$20.7M
-$22.7M
-$24.9M
-$27.4M
-$30.0M
-$33.0M
-$36.2M
-$39.8M
-$43.7M
-$47.9M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your CVM research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.